MAPT and Alzheimer disease: All these studies failed to find a positive effect of lithium on cognition, CSF p-tau and other AD-related blood or CSF biomarkers, conceivably because of small samples, short observation periods that were insufficient to detect any impact of neuroprotective agents, and the inclusion of subjects in more advanced stages of cognitive deterioration, i.e., mild, and moderate AD.